Merve Keskinkilic | Medical Oncology | Best Researcher Award

Dr. Merve Keskinkilic | Medical Oncology | Best Researcher Award

Medical Oncologist, Izmir Democracy University Buca Seyfi Demirsoy Training and Research Hospital Turkey

Merve Keskinkılıç is a dedicated Medical Oncologist at Burdur State Hospital with a strong academic background in Internal Medicine and Medical Oncology. She earned her M.D. from Dokuz Eylul University Faculty of Medicine and completed her Medical Oncology Fellowship at the same institution. Dr. Keskinkılıç has extensive clinical experience, having served as a Research Fellow at Emory University, USA. Fluent in English (C1 Advanced) and proficient in German (Elementary), she actively participates in international oncology research. Her expertise includes clinical trials, cancer treatment strategies, and translational oncology research, contributing significantly to advancements in the field.

Publication Profile

Scopus

Scholar

🎓 Education

Dr. Keskinkılıç completed her high school education at Balıkesir Science High School (2004-2008) before pursuing medicine at Dokuz Eylul University (2008-2014). She participated in an Oncology Exchange Program at Mansoura University, Egypt (2010). She later obtained an Associate Degree in Healthcare Management from Anadolu University (2014-2017). Her residency in Internal Medicine was completed at Celal Bayar University (2015-2016) and Dokuz Eylul University (2016-2019). She pursued a Medical Oncology Fellowship at Dokuz Eylul University (2019-2024) and is currently undertaking a PhD in Basic Oncology at Dokuz Eylul University Oncology Institute (since 2022). She also worked as a Research Fellow at Emory University, USA (2023).

💼 Experience

Dr. Keskinkılıç began her career as a General Practitioner at Balıkesir Susurluk State Hospital (2014-2015) before becoming a Research Assistant in Internal Medicine at Celal Bayar University (2015-2016) and later at Dokuz Eylul University (2016-2019). She served as a Specialist Doctor at Bitlis Mutki State Hospital (2019) and as a Fellow in Medical Oncology at Dokuz Eylul University (2019-2024). Currently, she is a Medical Oncologist at Burdur Public Hospital (2024-2025) and will join Izmir Democracy University Buca Seyfi Demirsoy Training and Research Hospital in 2025.

🏆 Awards & Honors

Dr. Keskinkılıç holds several prestigious certifications, including the Turkish Board of Internal Medicine Certificate (2018), Experimental Animal Use Certificate (2019), Oncology Clinical Research Training Certificate (2020), and ESMO Board of Examination Certificate (2023). She has also completed Good Clinical Practices (ICU) and Clinical Research Training and has received certifications in Research Ethics and Clinical Trials. Her contributions to oncology research and education have been recognized through multiple national and international accolades.

🔬 Research Focus

Dr. Keskinkılıç specializes in clinical oncology research, focusing on urothelial, bladder, gastric, prostate, and lung cancers. She is actively involved in multiple clinical trials, serving as a Sub-Investigator in research projects such as THOR (Urothelial Cancer), Niagara (Bladder Cancer), MK3475-859 (Gastric Cancer), Regeneron (Non-Small Cell Lung Cancer), and Radiant 20510 (Prostate Cancer). Her work emphasizes innovative treatment strategies, immunotherapy, and targeted cancer therapies, contributing to the development of advanced oncological treatments. Her internal medicine dissertation evaluated CMV DNA Antigenemia in Allogeneic Bone Marrow Transplant Patients.

Publication Top Notes

  • Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy
    • Authors: C. Karacin, B. Oksuzoglu, A. Demirci, M. Keskinkılıç, et al.
    • Journal: BMC Cancer, 2023
    • Citations: 20

 

  • Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer
    • Authors: S. Kahraman, E. Erul, M. Seyyar, O. Gumusay, et al.
    • Journal: Future Oncology, 2023
    • Citations: 13

 

  • Clinical outcomes of cyclin-dependent kinase 4–6 (CDK 4–6) inhibitors in patients with male breast cancer: a multicenter study
    • Authors: H. Ç. Yıldırım, E. Mutlu, E. Chalabiyev, M. Özen, et al.
    • Journal: The Breast, 2022
    • Citations: 13

 

  • The effect of low HER2 expression on treatment outcomes in metastatic hormone receptor-positive breast cancer patients treated with a combination of a CDK4/6 inhibitor and…
    • Authors: E. C. Yildirim, E. Atag, E. Coban, et al.
    • Journal: The Breast, 2023
    • Citations: 12

 

  • Efficacy of first-line CDK 4-6 inhibitors in premenopausal patients with metastatic breast cancer and the effect of dose reduction due to treatment-related neutropenia
    • Authors: H. C. Yildirim, C. Kapar, B. Koksal, et al.
    • Journal: Journal of Chemotherapy, 2024
    • Citations: 4

 

  • The prognostic indicator in breast cancer treated with CDK4/6 inhibitors: the prognostic nutritional index
    • Authors: M. Keskinkilic, H. S. Semiz, G. Polat, et al.
    • Journal: Future Oncology, 2023
    • Citations: 4

 

  • Antibody-Drug Conjugates in Triple Negative Breast Cancer
    • Authors: M. Keskinkilic, R. Sacks
    • Journal: Clinical Breast Cancer, 2024
    • Citations: 3

 

  • 194P Increased blood creatinine level due to CDK 4/6 inhibitor treatments: single center experience
    • Authors: M. Keskinkılıç, H. S. Semiz, T. Yavuzsen, A. Karaoglu
    • Journal: Annals of Oncology, 2022
    • Citations: 3

 

  • The prognostic nutritional index (PNI): A new biomarker for determining prognosis in metastatic castration-sensitive prostate carcinoma
    • Authors: H. I. Ellez, M. Keskinkilic, et al.
    • Journal: Journal of Clinical Medicine, 2023
    • Citations: 11

 

  • The role of immune checkpoint inhibition in triple-negative breast cancer
    • Authors: K. Tarekegn, M. Keskinkilic, T. J. Kristoff, S. T. Evans, K. Kalinsky
    • Journal: Expert Review of Anticancer Therapy, 2023
    • Citations: 10

 

  • The percentage of ALK-positive cells and the efficacy of first-line alectinib in advanced non-small cell lung cancer
    • Authors: M. Hizal, B. Bilgin, N. Paksoy, et al.
    • Journal: Journal of Cancer Research and Clinical Oncology, 2023
    • Citations: 5

 

  • CD47 (‘don’t eat me’ signal) expression levels and its relationship with clinicopathologic features in early‐stage prostate carcinoma
    • Authors: H. S. Semiz, Ü. Küçük, E. Kısa, M. Keskinkılıç, et al.
    • Journal: The Prostate, 2022
    • Citations: 5

 

  • A severe case of levothyroxine intoxication successfully treated in intensive care unit
    • Authors: Y. Savran, T. Mengi, M. Keskinkilic
    • Journal: Journal of Acute Disease, 2018
    • Citations: 11

 

 

AYOUB MARHOU | Medical physics| Young Scientist Award

Mr. AYOUB MARHOU | Medical physics| Young Scientist Award

Faculty of sciences, Mohammed first university Morocco

Marhou Ayoub, born on September 28, 1996, in Talsint, Morocco, is a dedicated Ph.D. candidate in Physics and Engineering at the Faculty of Sciences, Oujda. His expertise lies in theoretical physics and particle physics, driven by a strong academic background and research passion.

Professional Profile 

Education 🎓

2024: Final year of Doctorate in Physics and Engineering, Faculty of Sciences, Oujda. 2019: Began Ph.D. in Theoretical Physics and Particle Physics. 2019: Master’s in Physics of Matter and Radiation, Faculty of Sciences, Oujda (Bien). 2017: Bachelor’s in Physics, Faculty of Sciences, Oujda (Bien). 2014: Baccalauréat, Experimental Sciences, Benitadjit (Passable).

Experience 💻

2019: Radiotherapy internship (4 months), Hassan II Oncology Center, CHU Mohammed VI, Oujda. Proficient in Windows, Linux, UNIX, Microsoft Word, LibreOffice, and LaTeX2e. Skilled in programming languages: Fortran (learning), C, C++, and OOP. Expert in simulation tools like Geant4.

Awards and Honors 🏅

  • Recognized for academic excellence in Master’s and Bachelor’s studies.
  • Active contributor to high-level physics research projects and simulations.

Research Focus 🔬

Specializes in theoretical physics, particle physics, and radiation physics, emphasizing advanced computational simulations and programming to explore innovative solutions in physics and engineering.

Publications Top Noted

 

  1. The Impact Assessment of a Magnetic Field Dedicated to MRI During a Carbon-Therapy on Treatment Efficiency: Application to 1.5 T Magnetic Field
    • Authors: A. Marhou, A. Bazza, I. Habib-Allah, M. Zerfaoui, N. Chafi
    • Journal: Radiation Physics and Chemistry
    • Year: 2025
    • Volume: 227
    • Article ID: 112360
    • Citations: 0

 

  1. Assessment of Natural Radioactivity in Moroccan Bottled Drinking Waters Using Gamma Spectrometry
    • Authors: A. Bazza, M. Rhiyourhi, A. Marhou, M. Hamal
    • Journal: Environmental Monitoring and Assessment
    • Year: 2023
    • Volume: 195
    • Issue: 11
    • Article ID: 1307
    • Citations: 1

Shunsuke Suzuki | medical physics | Best Researcher Award

Mr. ‌ Shunsuke Suzuki| | Thermodynamics | Best Researcher Award

Mr at Shonan Kamakura General Hospital,  Japan

 I am an accomplished researcher and academic, currently pursuing a Ph.D. at the Graduate School of Engineering, Kyoto University. With a strong background in radiation therapy and dosimetry, my research has focused on radiation-induced secondary carcinogenesis and the development of precise γ-ray dosimetry methods for boron neutron capture therapy (BNCT). I have published several papers and presented at numerous conferences, contributing to advancements in proton therapy and BNCT. Currently, I am introducing the “nuBeam” accelerator-based BNCT system at Shonan Kamakura General Hospital and continue to innovate in the field of radiation dosimetry and cancer treatment technologies.

Profile

 

Education, Experience, and Academic Achievements 🎓

I conducted research on radiation-induced secondary carcinogenesis during my master’s course at the Graduate School of Medicine, Hokkaido University, and presented my findings at an academic conference. Following my master’s, I joined the Minami-Tohoku Cancer Proton Therapy Center, where I published a paper on radiation-induced secondary carcinogenesis in children due to different proton therapy irradiation methods. Currently, I work at Shonan Kamakura General Hospital, where I am introducing the accelerator-based boron neutron capture therapy system “nuBeam” and presenting research on its initial evaluation at conferences and in scholarly papers. Additionally, I am conducting research on developing γ-ray dosimetry in neutron fields, which has been published and will be presented at an international conference. I am also pursuing a doctoral degree at the Graduate School of Engineering, Kyoto University, and will graduate this year.

Contributions to Research & Development, Innovations, and Extension Activities 🧪

In the realm of boron neutron capture therapy (BNCT), the radiation emitted by the BNCT machine is directly linked to the patient dose. Therefore, accurately evaluating the gamma ray dose through measurement is crucial for introducing BNCT into clinical practice. Measurement methods for gamma ray doses in BNCT fields currently vary among facilities, necessitating a universally applicable and accurate method. In Japan, a custom-built thermoluminescent dosimeter (TLD) (Panasonic, UD-170LS) with beryllium oxide powder in a quartz glass tube is used for 𝛾 dose measurement, but it is no longer manufactured or commercially available. Consequently, I investigated a method combining a commercially available Mg2SiO4:Tb TLD (TOREC, TLD-MSO-S) with a 6LiF sintered capsule, verifying its efficacy for 𝛾 dose measurement in an accelerator-based (AB)-BNCT system.

Publications Top Notes 📝

  1. Initial evaluation of accelerator-based neutron source system at the Shonan Kamakura General Hospital
    • Authors: S. Suzuki, K. Nitta, T. Yagihashi, P. Eide, H. Koivunoro, N. Sato, S. Gotoh, et al.
    • Journal: Applied Radiation and Isotopes
    • Volume: 199
    • Article: 110898
    • Year: 2023

 

  1. Effectiveness of robust optimization against geometric uncertainties in TomoHelical planning for prostate cancer
    • Authors: T. Yagihashi, K. Inoue, H. Nagata, M. Yamanaka, A. Yamano, S. Suzuki, et al.
    • Journal: Journal of Applied Clinical Medical Physics
    • Volume: 24
    • Issue: 4
    • Article: e13881
    • Year: 2023

 

  1. Impact of lifetime attributable risk of radiation-induced secondary cancer in proton craniospinal irradiation with vertebral-body-sparing for young pediatric patients
    • Authors: S. Suzuki, T. Kato, M. Murakami
    • Journal: Journal of Radiation Research
    • Volume: 62
    • Issue: 2
    • Pages: 186-197
    • Year: 2021

 

  1. Evaluation of dose effects of two types of tomotherapy couch and examination of its optimization
    • Authors: S. Suzuki, T. Inoue, A. Yamano, H. Nagata
    • Journal: Journal of the Korean Physical Society
    • Volume: 83
    • Issue: 12
    • Pages: 984-992
    • Year: 2023

 

  1. Optimization of TomoTherapy couch density in the RayStation treatment-planning system
    • Authors: S. Suzuki, T. Inoue, T. Yagihashi, H. Nagata
    • Journal: Journal of the Korean Physical Society
    • Volume: 83
    • Issue: 12
    • Pages: 993-1002
    • Year: 2023

 

  1. Relative Biological Effectiveness Values of Spot-scanning Proton Beam Therapy at Shonan Kamakura General Hospital
    • Authors: S. Shiba, M. Yamanaka, K. Matsumoto, A. Yamano, T. Shimo, S. Suzuki, et al.
    • Journal: in vivo
    • Volume: 37
    • Issue: 3
    • Pages: 1016-1021
    • Year: 2023
    • Abstract: This research investigates the Relative Biological Effectiveness (RBE) values of spot-scanning proton beam therapy at Shonan Kamakura General Hospital. The findings contribute to understanding the biological impact and therapeutic advantages of proton beam therapy in clinical settings.

.